Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1087)	12/2/1999 9:04:00 AM
From: biowa	Respond to of 4974

NeuroInvestment, <<the treatment staff being more motivated and providing a higher level of care in the belief that something 'special' is being given>> You hit it on the head (and not just in neuro... <g>), add to that the greater level of attention paid to the patient just because of enrollment: tighter diagnosis, additional and more frequent lab values, greater attention from the investigating physician, more attention to medication regimens. On top of that, the standard of care in some diseases is advancing so rapidly that placebo is almost certain to do better than it did when the trial was designed or even initiated. biowa